GJ19
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with KD values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy[1].
Product Specifications
UNSPSC
12352100
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.02
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@H](O)[C@H](C(O)=O)NCC1=CC(Cl)=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)C=C1OCC4=CC=C(S(=O)(F)=O)C=C4
Molecular Formula
C32H31ClFNO7S
Molecular Weight
628.11
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ETS1 (Marker of Tumor Metastasis) (ETS1/1801), Biotin conjugate, 0.1mg/mL
Uroplakin 1B (Urothelial Differentiation Marker) (UPK1B/3102), CF594 conjugate, 0.1mg/mL
